スタッフ ログイン
Japanese |
English
ご質問・ご要望
一覧
検索
生物種別閲覧
登録
統計情報
検索
ホーム
一覧
論文
特許
論文 - 一覧
«
»
10 Hits
検索条件 : 絞込み (MeSH = Adenocarcinoma of Lung / genetics)
生物種
リソース名
RRC ID
タイトル
ジャーナル
公開日
外部リンク
ヒト・動物細胞
PC-9(RCB4455)
76383
TRIM28
is a distinct prognostic biomarker that worsens the tumor immune microenvironment in lung adenocarcinoma.
Aging (Albany NY)
2020-10-22
Pubmed
Full text
ヒト・動物細胞
PC-9(RCB445)
75065
ROR1-CAVIN3 interaction required for caveolae-dependent endocytosis and pro-survival signaling in lung adenocarcinoma.
Oncogene
2019-6-1
Pubmed
Full text
ヒト・動物細胞
LU99(RCB1900)
,
LU65(RCB1967)
,
IA-LM(RCB0554)
68965
The KRAS
G12C
Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.
Cancer Discov
2020-1-1
Pubmed
Full text
ヒト・動物細胞
PC-9(RCB4455)
68849
Suppression of tumor immune microenvironment via microRNA-1 after epidermal growth factor receptor-tyrosine kinase inhibitor resistance acquirement in lung adenocarcinoma.
Cancer Med
2021-1-1
Pubmed
Full text
ヒト・動物細胞
A549
63101
(Pro)renin receptor/ATP6AP2 is required for autophagy and regulates proliferation in lung adenocarcinoma cells.
Genes Cells
2020-12-1
Pubmed
Full text
ヒト・動物細胞
LC-2/ad(RCB0440)
60020
Clinicopathological and prognostic significance of nuclear UGDH localization in lung adenocarcinoma.
Biomed Res
2019-1-1
Pubmed
Full text
ヒト・動物細胞
A549(RCB0098)
59846
Stratifin Inhibits SCF
FBW7
Formation and Blocks Ubiquitination of Oncoproteins during the Course of Lung Adenocarcinogenesis.
Clin Cancer Res
2019-5-1
Pubmed
Full text
遺伝子材料
pENTR4-H1 (RDB04395)
,
CS-RfA-CG (RDB04390)
,
pCAG-HIVgp (RDB04394)
,
pCMV-VSV-G-RSV-Rev (RDB04393)
55029
Mathematical analysis of gefitinib resistance of lung adenocarcinoma caused by MET amplification.
Biochem Biophys Res Commun
2019-4-9
Pubmed
Full text
ヒト・動物細胞
PC-9(RCB4455)
54821
AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells.
Nat Commun
2019-1-16
Pubmed
Full text
ヒト・動物細胞
TE-4(RCB2097)
54001
Small molecule inhibitors and CRISPR/Cas9 mutagenesis demonstrate that SMYD2 and SMYD3 activity are dispensable for autonomous cancer cell proliferation.
PLoS One
2018-6-1
Pubmed
Full text